AGT is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, Phenylketonuria (PKU) and Hepatocellular carcinoma (liver cancer, or HCC). Our drug candidates have achieved initial proof of concept in preclinical studies and have potential to deliver cost-effective therapies that are better targeted and more potent with fewer side effects. AGT’s drugs will treat symptomatic disease, but are intended to provide durable cures that extend the length and improve the quality of patients’ lives.